Novartis exec pushed out over Zolgensma data scandal denies wrongdoing

pharmafile | August 21, 2019 | News story | Research and Development AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma 

Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement that he “categorically denies any wrongdoing.”

Speaking through a lawyer, Kaspar said he “stands proudly behind the safety and efficacy” of the $2.1 million gene therapy Zolgensma, and that he is “prepared to assert his rights and defend his conduct accordingly.”

The statement from law firm Heuston Hannigan, who previously represented Elon Musk, says: “Dr Brian Kaspar is a respected member of the scientific community with an impeccable record. He stands proudly behind the safety and efficacy of the drug that he and his team worked so hard to develop, and which remains an FDA-approved drug that is saving the lives of children who suffer from Spinal Muscular Atrophy.

Advertisement

“He has cooperated with Avexis’ internal investigation, and he categorically denies any wrongdoing. He is prepared to assert his rights and defend his conduct accordingly. Dr Kaspar continues to wish clinicians and the company continued success in the treatment of children with this deadly and devastating disease.”

Louis Goss

Related Content

Novartis receives SMC approval for early breast cancer treatment

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631_1

Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation

Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …

The Gateway to Local Adoption Series

Latest content